INOVIQ Ltd (ASX:IIQ) released in-vitro POC data showing its engineered exosomes (EEVs) target and kill breast cancer. Highlights: ✔ Breast cancer targeting proteins (CARs) expressed in immune cell-exosomes ✔ EXO-ACE™ isolation delivers 80% recovery and 95% purity ✔ 75% breast cancer

Check out MST Financial's update note on INOVIQ Ltd (ASX:IIQ) engineered exosomes kill breast cancer in-vitro. Access the full report here: bit.ly/4b4i041 #EXOACE #INOVIQ #Therapeutics #exosomes #research #cancer

Join INOVIQ Ltd (ASX:IIQ) CEO, @Leearnehinch as she presents at the MST Access Hidden Gems in Life Sciences webinar on Thursday, 13 June 2024, at 3:00PM (AEST). Register here: bit.ly/3X80c4z #INOVIQ #MSTFinancial #Webinar #LifeSciences #HiddenGems #Biotech #SmallCaps

INOVIQ Ltd (ASX:IIQ) is pleased to announce that it has successfully completed an A$7 million placement to institutional and sophisticated investors. To see announcement & investor presentation go to: bit.ly/3xlnsBq #INOVIQ #EXONET #Biotech #SmallCaps #CapitalRaise

INOVIQ Ltd (ASX:IIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease. To find out more go to: bit.ly/3KFwhsZ #INOVIQ #NEURONET #Alzheimers #Exosomes #Therapeutics #Diagnostics #Research

INOVIQ Ltd (ASX:IIQ) is pleased to announce the successful completion of the share purchase plan (SPP) with applications accepted for A$2.379m. Total funds raised of A$9.379m under SPP and placement. Go to bit.ly/3VRRO75 to read more. #INOVIQ #EXONET #Biotech #SmallCaps

INOVIQ Ltd (ASX:IIQ) has released its June quarterly business update and Appendix 4C highlighting increasing revenue from its research tools, progress on its cancer diagnostic and therapeutic programs and a solid cash balance of $9.233m at 30 June 2024. Go to bit.ly/4d1Nf1h to

INOVIQ Ltd (ASX:IIQ) is pleased to announce that it has further validated its NEURO-NET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD). Initial validation studies in PD showed: ✔️NEURO-NET™ enriches known protein biomarkers of neurodegenerative disease

Daffodil Day raises awareness and much-needed funds for cancer research. At INOVIQ Ltd (ASX:IIQ) we are committed to saving lives through diagnostics and therapeutics cancer research. To find out more visit daffodilday.com.au #DaffodilDay #CancerResearch #INOVIQ #Diagnositcs

INOVIQ Ltd (ASX:IIQ) is pleased to welcome Mary Harney as a Non-Executive Director, effective from 1 October 2024. Mary is an experienced Non-Executive Director and Chief Executive, bringing a wealth of expertise in applied life science research, biopharmaceutical regulatory affairs, and

October marks Breast Cancer Awareness Month. INOVIQ Ltd (ASX:IIQ) is developing better diagnostics and therapeutics for earlier detection and treatment of breast cancer. Show your support by wearing pink and starting important conversations with your loved ones about early detection. To

INOVIQ Ltd (ASX:IIQ) is holding it 2024 Annual General Meeting this Thursday 28th November at 10am (AEDT). To access the Notice of Meeting go to: inoviq.com/site/pdf/3769d… Business updates will be provided by INOVIQ Chair, David Williams and CEO, Dr Leearne Hinch. Should you wish to join

INOVIQ Ltd (ASX:IIQ) has achieved a significant milestone for its EXO-OC ovarian cancer screening test. An independent patient validation study in over 500 samples validated the test’s biomarkers and diagnostic performance, detecting ovarian cancer across all stages with overall accuracy

INOVIQ Ltd (ASX:IIQ) has successfully completed disease-specificity testing for breast cancer. The test has been analytically and clinically validated to detect breast cancer across all stages (81% sensitivity and 93% specificity), key breast cancer types and subtypes, and is effective

On Friday, 6 December, INOVIQ Ltd (ASX:IIQ) CEO, Dr. Leearne Hinch was interviewed by Share Cafe about our breakthrough results for INOVIQ’s ovarian cancer test. Catch the full interview here: bit.ly/49umYb3 Don’t forget to register for the Share Cafe Hidden Gems Webinar (“Sip

INOVIQ Ltd (ASX:IIQ) has successfully completed in vitro proof-of-concept (POC) for its exosome therapeutic program in breast cancer cells. Immortalised natural killer (NK) cells were engineered to continuously produce exosomes to target and kill breast cancer. CAR-NK-exosomes deliver

On 13 December, INOVIQ Ltd (ASX:IIQ) CEO, Dr Leearne Hinch presented at Share Cafe’s Hidden Gems, ‘Sip and Learn’ webinar. To watch the presentation, go to: bit.ly/3ZzrlwV #ShareCafe #HiddenGems #SipandLearn #Webinar #SmallCap #Biotech #Therapeutics #Diagnostics #Investor

INOVIQ Ltd (ASX:IIQ) proudly supports #WorldCancerDay 🌍 We are dedicated to pioneering next-gen exosome diagnostics and therapeutics to revolutionise cancer detection and treatment. Our mission is to catch cancer earlier and create more effective therapies, bringing hope and better

INOVIQ Ltd (ASX:IIQ) stands united in the fight against ovarian cancer this Ovarian Cancer Awareness Month. We are committed to advancing next-gen exosome diagnostics and therapeutics to detect ovarian cancer earlier and enable more effective and targeted treatment. Our goal is to bring

INOVIQ Ltd (ASX:IIQ) is collaborating with UQ News to develop INOVIQ’s EXO-OC screening test for the early detection of ovarian cancer. Previous studies have shown overall accuracy of 94% for detection of ovarian cancer across all stages and achieved a sensitivity of more than 90% and